Literature DB >> 17278106

Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.

Hiroki Yano1, Takashi Ishida, Atsushi Inagaki, Toshihiko Ishii, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) patients are highly immunocompromised, but the underlying mechanism responsible for this state remains obscure. Recent studies demonstrated that FOXP3, which is a master control gene of naturally occurring regulatory T (Treg) cells, is expressed in the tumor cells from a subset of patients with ATLL. Since most ATLL cells express both CD4 and CD25, these tumors might originate from CD4(+)CD25(+)FOXP3(+) Treg cells, based on their phenotypic characteristics. However, whether ATLL cells actually function as Treg cells has not yet been clearly demonstrated. Here, we show that ATLL cells from a subset of patients are not only hypo-responsive to T-cell receptor-mediated activation, but also suppress the proliferation of autologous CD4(+) non-ATLL cells. Furthermore, ATLL cells from this subset of patients secrete only small amounts of IFN-gamma, and suppress IFN-gamma production by autologous CD4(+) non-ATLL cells. These are the first data showing that ATLL cells from a subset of patients function as Treg cells in an autologous setting. The present study provides novel insights into understanding the immunopathogenesis of ATLL, i.e., how HTLV-1-infected cells can survive in the face of host immune responses. It also adds to our understanding of ATLL patients' severely immunocompromised state. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278106     DOI: 10.1002/ijc.22536

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A.

Authors:  Nicholas Paul Casey; Hiroshi Fujiwara; Toshiki Ochi; Masaki Yasukawa
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

2.  Epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional suppression of Tregs.

Authors:  Monique R Anderson; Yoshimi Enose-Akahata; Raya Massoud; Nyater Ngouth; Yuetsu Tanaka; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-21       Impact factor: 4.147

Review 3.  Adult T-cell leukemia/lymphoma and HTLV-1.

Authors:  Renaud Mahieux; Antoine Gessain
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

4.  The combination of IκB kinase β inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells.

Authors:  Chie Nishioka; Takayuki Ikezoe; Jing Yang; Keiko Udaka; Akihito Yokoyama
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

5.  Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.

Authors:  Masato Saito; Toshihiko Ishii; Itaru Urakawa; Asuka Matsumoto; Ayako Masaki; Asahi Ito; Shigeru Kusumoto; Susumu Suzuki; Takeshi Takahashi; Akimichi Morita; Hiroshi Inagaki; Shinsuke Iida; Takashi Ishida
Journal:  Blood Adv       Date:  2020-05-26

6.  Foxp3-dependent transformation of human primary CD4+ T lymphocytes by the retroviral protein tax.

Authors:  Li Chen; Dan Liu; Yang Zhang; Huan Zhang; Hua Cheng
Journal:  Biochem Biophys Res Commun       Date:  2015-09-14       Impact factor: 3.575

Review 7.  Implication of the HTLV-I bZIP factor gene in the leukemogenesis of adult T-cell leukemia.

Authors:  Yorifumi Satou; Masao Matsuoka
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

8.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

9.  Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study.

Authors:  Kentaro Yonekura; Shigeru Kusumoto; Ilseung Choi; Nobuaki Nakano; Asahi Ito; Youko Suehiro; Yoshitaka Imaizumi; Makoto Yoshimitsu; Kisato Nosaka; Eiichi Ohtsuka; Michihiro Hidaka; Tatsuro Jo; Hidenori Sasaki; Yukiyoshi Moriuchi; Masao Ogata; Hiro Tatetsu; Kenji Ishitsuka; Yasushi Miyazaki; Ryuzo Ueda; Atae Utsunomiya; Takashi Ishida
Journal:  Blood Adv       Date:  2020-10-27

Review 10.  Regulatory T cells and treatment of cancer.

Authors:  Tyler J Curiel
Journal:  Curr Opin Immunol       Date:  2008-05-27       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.